tPA Antibody (2A153): sc-59721
- tPA Antibody (2A153) is a mouse monoclonal IgG, cited in 6 publications, provided at 100 µg/ml
- raised against full length tPA of human origin
- recommended for detection of tPA of human origin by WB and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for tPA Antibody (2A153). This work is in progress.
QUICK LINKS
SEE ALSO...
tPA Antibody (2A153) is a mouse monoclonal IgG antibody that detects tissue plasminogen activator (tPA) in human samples through applications such as western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). tPA plays a crucial role in the fibrinolytic system, primarily facilitating the breakdown of fibrin in blood clots, which is essential for maintaining normal blood flow and preventing excessive clot formation. tPA is secreted by endothelial cells and is found in the bloodstream, where tPA acts to convert plasminogen into plasmin, the active enzyme responsible for degrading fibrin. The regulation of tPA is vital, as an imbalance can lead to pathological conditions such as thrombosis or hemorrhage. Additionally, tPA interacts with various proteins, including plasminogen activator inhibitor-1 (PAI-1), which modulates tPA activity and stability. Anti-tPA antibody (2A153) is an invaluable tool for researchers studying the dynamics of fibrinolysis and its implications in cardiovascular diseases, providing insights into the mechanisms of clot resolution and the potential for therapeutic interventions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
tPA Antibody (2A153) References:
- Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. | O'Rourke, J., et al. 2005. J Neurosci Res. 79: 727-33. PMID: 15678511
- Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. | Adibhatla, RM. and Hatcher, JF. 2008. CNS Neurol Disord Drug Targets. 7: 243-53. PMID: 18673209
- Anti-tissue plasminogen activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation. | Yang, D. and Kuan, CY. 2015. CNS Neurosci Ther. 21: 367-73. PMID: 25475942
- Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. | Chevilley, A., et al. 2015. Front Cell Neurosci. 9: 415. PMID: 26528141
- Tissue plasminogen activator (tPA) attenuates propofol-induced apoptosis in developing hippocampal neurons. | Liang, C., et al. 2016. Springerplus. 5: 475. PMID: 27217990
- Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of in vitro but not of in vivo fertilisation in the mouse. | García-Vázquez, FA., et al. 2019. Reprod Fertil Dev. 31: 433-442. PMID: 30304664
- Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study. | Yu, X., et al. 2022. J Thromb Thrombolysis. 53: 291-301. PMID: 34757546
- Blood tissue Plasminogen Activator (tPA) of liver origin contributes to neurovascular coupling involving brain endothelial N-Methyl-D-Aspartate (NMDA) receptors. | Furon, J., et al. 2023. Fluids Barriers CNS. 20: 11. PMID: 36737775
- Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders. | Mennesson, M. and Revest, JM. 2023. Int J Mol Sci. 24: PMID: 36901924
- Tissue-type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease. | Tao, Y., et al. 2023. MedComm (2020). 4: e392. PMID: 37808270
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
tPA Antibody (2A153) | sc-59721 | 100 µg/ml | $322.00 |